| |||||||||||||
| Rating | Health Concerns |
|---|---|
![]() |
Phenylketonuria (for deficiency) |
![]() |
|
Reliable and relatively consistent scientific data showing a substantial health benefit. Contradictory, insufficient, or preliminary
studies suggesting a health benefit or minimal health benefit. For an herb, supported by traditional use but
minimal or no scientific evidence. For a supplement, little scientific support and/or minimal
health benefit. | |
Some people affected by PKU are deficient in tyrosine. Tyrosine levels are occasionally low in depressed people.11 Any person losing large amounts of protein, such as those with some kidney diseases, may be deficient in several amino acids, including tyrosine.12
Most people should not supplement with L-tyrosine. Some human research with people suffering from a variety of conditions used 100 mg per 2.2 pounds of body weight, equivalent to about 7 grams per day for an average-sized person. The appropriate amount to use in people with PKU is not known, therefore, the monitoring of blood levels by a physician is recommended.
L-tyrosine has not been reported to cause any serious side effects. However, it is not known whether long-term use of L-tyrosine, particularly in large amounts (such as more than 1,000 mg per day) is safe. For that reason, long-term use of L-tyrosine should be monitored by a doctor.
Vitamin B6, folic acid, and copper are necessary for conversion of L-tyrosine into neurotransmitters.
Are there any drug
interactions?
Certain medicines may interact with L-tyrosine. Refer to drug interactions for a list of those medicines.
1. Gelenberg AJ, Gibson CJ, Wojcik JD. Neurotransmitter precursors for the treatment of depression. Psychopharmacol Bull 1982;18:7–18.
2. Meyer JS, Welch KMA, Deshmuckh VD, et al. Neurotransmitter precursor amino acids in the treatment of multi-infarct dementia and Alzheimer’s disease. J Am Geriatr Soc 1977;7:289–98.
3. Banderet LE, Lieberman HR. Treatment with tyrosine, a neurotransmitter precursor, reduces environmental stress in humans. Brain Res Bull 1989;22:759–62.
4. Salter CA. Dietary tyrosine as an aid to stress resistance among troops. Mil Med 1989;154:144–6.
5. Neri DF, Wiegmann D, Stanny RR, et al. The effects of tyrosine on cognitive performance during extended wakefulness. Aviat Space Environ Med 1995;66:313–9.
6. Deijen JB, Wientjes CJ, Vullinghs HF, et al. Tyrosine improves cognitive performance and reduces blood pressure in cadets after one week of a combat training course. Brain Res Bull 1999;48:203–9.
7. Shurtleff D, Thomas JR, Schrot J, et al. Tyrosine reverses a cold-induced working memory deficit in humans. Pharmacol Biochem Behav 1994;47:935–41.
8. Deijen JB, Orlebeke JF. Effect of tyrosine on cognitive function and blood pressure under stress. Brain Res Bull 1994;33:319–23.
9. Dollins AB, Krock LP, Storm WF, et al. L-tyrosine ameliorates some effects of lower body negative pressure stress. Physiol Behav 1995;57:223–30.
10. Koch R. Tyrosine supplementation for phenylketonuria treatment. Am J Clin Nutr 1996;64:974–5.
11. Chiaroni P, Azorin JM, Bovier P, et al. A multivariate analysis of red blood cell membrane transports and plasma levels of L-tyrosine and L-tryptophan in depressed patients before treatment and after clinical improvement. Neuropsychobiology 1990;23:1–7.
12. Alvestrand A, Ahlberg M, Forst P, Bergstrom J. Clinical results of long-term treatment with a low protein diet and a new amino acid preparation in patients with chronic uremia. Clin Nephrol 1983;19:67–73.
| |||||||